MRC/NICE's methodology research program

31 May 2009

The UK's Medical Research Council has issued a GBP2.0-million ($3.3 million) call for proposals in methodology research in collaboration  with the National Institute for Health and Clinical Excellence (NICE),  which recommends medical treatment under the National Health Service  excluding Scotland.

The need for methodological research to underpin decision-making by the  NICE was highlighted in a House of Commons Health Select Committee  Report in 2008. Since then, the MRC has been working with NICE to  identify its methodological research priorities and the new call for  proposals has been developed in response to the requirements identified.   Commenting on the announcement, Peter Littlejohns, NICE Clinical and  Public Health Director, said: "NICE is tasked with making some of the  most difficult decisions in public life, decisions that have an impact  on the millions of people who use the NHS. It's therefore vital for  people to continue to have confidence not just in the guidance we  produce, but also in the processes and methods we use to produce it."

Prof Littlejohns continued by noting that "this research will address  some of the key issues in our process and methodology. Of particular  importance are the issues around how we measure health-related quality  of life. This is translational research, it's about getting things into  our process and methodology that will make a real difference to  patients."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight